Ionis licenses investigational Alzheimer’s therapy

CARLSBAD, Calif., Dec. 19, 2019 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that Biogen, a collaboration partner for neurological diseases, has licensed IONIS-MAPTRx, an antisense therapy designed to selectively…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.